RUNX2 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), heightened expression of miR-218 promotes apoptosis and causes cell cycle arrest at the G0/S checkpoint, enhancing sensitivity to cisplatin by downregulating Runx2 [28].